Gheorghe

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/250773/publications.pdf

Version: 2024-02-01

107 3,113 28 52 papers citations h-index g-index

107 107 107 4082 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis. Nephrology Dialysis Transplantation, 2022, 37, 1281-1288.	0.4	7
2	Rationale and design of the safe and timely antithrombotic removal - ticagrelor (STAR-T) trial: A prospective, multi-center, double-blind, randomized controlled trial evaluating reductions in postoperative bleeding with intraoperative removal of ticagrelor by the drugsorbâ,,¢-ATR device in patients undergoing cardiothoracic surgery within 48 hours from last ticagrelor dose. American Heart Journal, 2022, 245, 19-28.	1.2	4
3	Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis: The AVATAR Trial. Circulation, 2022, 145, 648-658.	1.6	130
4	Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2022, 29, 71-78.	1.4	13
5	Correlation Between 24-Hour Urine Protein and Random Urine Protein-Creatinine Ratio in Amyloid Light-Chain Amyloidosis. Kidney Medicine, 2022, 4, 100427.	1.0	4
6	Differences in the cytogenetic underpinnings of AL amyloidosis among African Americans and Caucasian Americans. Blood Cancer Journal, 2022, 12, .	2.8	0
7	Adaptive disclosure, a combat-specific PTSD treatment, versus cognitive-processing therapy, in deployed marines and sailors: A randomized controlled non-inferiority trial. Psychiatry Research, 2021, 297, 113761.	1.7	33
8	Clinical Characteristics, Treatment Regimens, and Survival in Elderly Patients with AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 425-426.	0.2	4
9	Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer Journal, 2021, 11, 139.	2.8	45
10	Greater plaque burden and cholesterol content may explain an increased incidence of non-culprit events in diabetic patients: a Lipid-Rich Plaque substudy. European Heart Journal Cardiovascular Imaging, 2021, , .	0.5	1
11	A 40-Year Natural History Study of Overall Survival and Primary Causes of Death in Systemic Light Chain (AL) Amyloidosis. Blood, 2021, 138, 155-155.	0.6	2
12	517. Subcutaneous Sarilumab for the Treatment of Hospitalized patients with Moderate to Severe COVID19 Disease: A Pragmatic, Embedded, Multi-Center Randomized Clinical Trial. Open Forum Infectious Diseases, 2021, 8, S360-S360.	0.4	0
13	Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male, 2020, 23, 81-92.	0.9	58
14	Establishment of brain natriuretic peptide ―based criteria for evaluating cardiac response to treatment in light chain (AL) amyloidosis. British Journal of Haematology, 2020, 188, 424-427.	1.2	25
15	Perioperative outcomes after lower extremity bypass and peripheral vascular interventions in patients with morbid obesity and superobesity. Journal of Vascular Surgery, 2020, 71, 567-574.e4.	0.6	17
16	Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities. Blood Cancer Journal, 2020, 10, 118.	2.8	21
17	Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents Versus Thin Durable-Polymer Everolimus-Eluting Stents for Coronary Revascularization. JACC: Cardiovascular Interventions, 2020, 13, 1343-1353.	1.1	68
18	Remission of type 2 diabetes following longâ€term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11â€year data from a realâ€world registry study. Diabetes, Obesity and Metabolism, 2020, 22, 2055-2068.	2.2	55

#	Article	IF	CITATIONS
19	Racial and Ethnic Disparities in Systemic AL Amyloidosis: Examining Differences in Clinical Presentation and Outcomes. Blood, 2020, 136, 51-51.	0.6	O
20	Patients with end-stage renal disease have poor outcomes after endovascular abdominal aortic aneurysm repair. Journal of Vascular Surgery, 2019, 69, 405-413.	0.6	16
21	Do 5α-Reductase Inhibitors Raise Circulating Serum Testosterone Levels? A Comprehensive Review and Meta-Analysis to Explaining Paradoxical Results. Sexual Medicine Reviews, 2019, 7, 95-114.	1.5	5
22	Factors Associated with Wound Complications after Open Femoral Artery Exposure for Elective Endovascular Abdominal Aortic Aneurysm Repair. International Journal of Angiology, 2019, 28, 124-129.	0.2	13
23	Prevalence and prognostic value of Dâ€dimer elevation in patients with AL amyloidosis. American Journal of Hematology, 2019, 94, 1098-1103.	2.0	12
24	Comparison of Early and Late Post-operative Outcomes after Supra-inguinal Bypass for Aortoiliac Occlusive Disease. European Journal of Vascular and Endovascular Surgery, 2019, 58, 529-537.	0.8	13
25	Design and rationale of a randomized noninferiority trial to evaluate the SurVeil drug-coated balloon in subjects with stenotic lesions of the femoropopliteal artery — the TRANSCEND study. American Heart Journal, 2019, 209, 88-96.	1.2	4
26	The effect of the duration of preoperative smoking cessation timing on outcomes after elective open abdominal aortic aneurysm repair and lower extremity bypass. Journal of Vascular Surgery, 2019, 70, 1851-1861.	0.6	19
27	Predictors of Mortality in Light Chain Cardiac Amyloidosis with Heart Failure. Scientific Reports, 2019, 9, 8552.	1.6	31
28	National criteria for academic appointment in vascular surgery. Journal of Vascular Surgery, 2019, 69, 1559-1565.	0.6	9
29	Long term outcome of patients treated on clinical trials of immunomodulatory agents for the treatment of Immunoglobulin light chain (AL) amyloidosis: A pooled analysis. American Journal of Hematology, 2019, 94, E194-E196.	2.0	5
30	Acid-suppressive medications and risk of pneumonia in acute stroke patients: A systematic review and meta-analysis. Journal of the Neurological Sciences, 2019, 400, 122-128.	0.3	18
31	Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study. Diabetes Care, 2019, 42, 1104-1111.	4.3	116
32	A commentary on: statistical inference problems in sequential parallel comparison designs. Journal of Biopharmaceutical Statistics, 2019, 29, 1130-1133.	0.4	4
33	Long-term outcome of kidney transplantation in AL amyloidosis. Kidney International, 2019, 95, 405-411.	2.6	57
34	Development and validation of a survival staging system incorporating BNP in patients with light chain amyloidosis. Blood, 2019, 133, 215-223.	0.6	118
35	Association of frailty index with perioperative mortality and in-hospital morbidity after elective lower extremity bypass. Journal of Vascular Surgery, 2019, 69, 863-874.e1.	0.6	27
36	Comparison of one-stage and two-stage upper arm brachiobasilic arteriovenous fistula in the Vascular Quality Initiative. Journal of Vascular Surgery, 2019, 69, 1187-1195.e2.	0.6	12

#	Article	IF	Citations
37	SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients. Journal of the Endocrine Society, 2019, 3, .	0.1	O
38	OR21-2 Lipid Profiles Improve in Men With Hypogonadism and Pre-existing Cardiovascular Disease Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): 10-year Data From a Controlled Registry Study in a Urological Setting. Journal of the Endocrine Society, 2019, 3, .	0.1	0
39	SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting. Journal of the Endocrine Society, 2019, 3, .	0.1	O
40	SUN-055 Reduction of Mortality and Major Adverse Cardiovascular Events (MACE) in Men with Hypogonadism Treated with Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting. Journal of the Endocrine Society, 2019, 3, .	0.1	0
41	SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting. Journal of the Endocrine Society. 2019. 3	0.1	1
42	MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting. Journal of the Endocrine Society, 2019, 3, .	0.1	0
43	Outcomes of Peripheral Vascular Interventions in Select Patients With Lower Extremity Acute Limb Ischemia. Journal of the American Heart Association, 2018, 7, .	1.6	10
44	Association of Prenatal Ultrasonography and Autism Spectrum Disorder. JAMA Pediatrics, 2018, 172, 336.	3.3	18
45	Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2018, 25, 62-67.	1.4	108
46	Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation. American Journal of Hematology, 2018, 93, E129-E132.	2.0	6
47	External validation of Vascular Study Group of New England risk predictive model of mortality after elective abdominal aorta aneurysm repair in the Vascular Quality Initiative and comparison against established models. Journal of Vascular Surgery, 2018, 67, 143-150.	0.6	27
48	Bioresorbable polymer drug-eluting stents – Authors' reply. Lancet, The, 2018, 391, 936-937.	6.3	O
49	Long-Term Testosterone Therapy Improves Urinary and Sexual Function, and Quality of Life in Men with Hypogonadism: Results from a Propensity Matched Subgroup of a Controlled Registry Study. Journal of Urology, 2018, 199, 257-265.	0.2	69
50	Perioperative outcomes after reoperative carotid endarterectomy are worse than expected. Journal of Vascular Surgery, 2018, 67, 793-798.	0.6	8
51	Patient and Aneurysm Characteristics Predicting Prolonged Length of Stay After Elective Open AAA Repair in the Endovascular Era. Vascular and Endovascular Surgery, 2018, 52, 5-10.	0.3	4
52	A New Overall-Subgroup Simultaneous Test for Optimal Inference in Biomarker-Targeted Confirmatory Trials. Statistics in Biosciences, 2018, 10, 297-323.	0.6	3
53	Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents Versus Thin Durable Polymer Everolimus-Eluting Stents. Journal of the American College of Cardiology, 2018, 72, 3287-3297.	1.2	73
54	Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms. Investigative and Clinical Urology, 2018, 59, 399.	1.0	20

#	Article	IF	CITATIONS
55	Improved access to health care in Massachusetts after 2006 Massachusetts Healthcare Reform Law is associated with a significant decrease in mortality among vascular surgery patients. Journal of Vascular Surgery, 2018, 68, 1193-1202.e1.	0.6	11
56	Never events after hepatopancreatobiliary operations. American Journal of Surgery, 2018, 216, 1129-1134.	0.9	5
57	Features of atrial fibrillation in wildâ€type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Failure, 2018, 5, 772-779.	1.4	89
58	Contemporary open repair of ruptured abdominal aortic aneurysms. Journal of Vascular Surgery, 2017, 65, 1023-1028.	0.6	17
59	Morbidity and mortality after emergency lower extremity embolectomy. Journal of Vascular Surgery, 2017, 65, 754-759.	0.6	8
60	Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism. Journal of Cardiovascular Pharmacology and Therapeutics, 2017, 22, 414-433.	1.0	109
61	The association of Carotid Revascularization Endarterectomy versus Stent Trial (CREST) and Centers for Medicare and Medicaid Services Carotid Guideline Publication on utilization and outcomes of carotid stenting among $\hat{a} \in \hat{b}$ high-risk $\hat{a} \in \hat{b}$ patients. Journal of Vascular Surgery, 2017, 66, 104-111.e1.	0.6	17
62	Role of language discordance in complication and readmission rate after infrainguinal bypass. Journal of Vascular Surgery, 2017, 66, 1473-1478.	0.6	21
63	Outcomes of endovascular and open surgical repair of ruptured abdominal aortic aneurysms in elderly patients. Journal of Vascular Surgery, 2017, 66, 64-70.	0.6	32
64	Design and implementation of electronic health record integrated clinical prediction rules (iCPR): a randomized trial in diverse primary care settings. Implementation Science, 2017, 12, 37.	2.5	27
65	The six-minute walk test in patients with AL amyloidosis: a single centre case series. British Journal of Haematology, 2017, 177, 388-394.	1.2	12
66	Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. Lancet, The, 2017, 390, 1843-1852.	6.3	214
67	Early carotid endarterectomy performed 2 to 5 days after the onset of neurologic symptoms leads to comparable results to carotid endarterectomy performed at later time points. Journal of Vascular Surgery, 2017, 66, 1719-1726.	0.6	24
68	Hematologic relapse in AL amyloidosis after high-dose melphalan and stem cell transplantation. Blood, 2017, 130, 1383-1386.	0.6	30
69	Preoperative Risk Factors Predict Protracted Hospital Length of Stay after Elective Endovascular Abdominal Aortic Aneurysm Repair. Annals of Vascular Surgery, 2017, 43, 73-78.	0.4	13
70	Impact of Compliance on Dysphagia Rehabilitation in Head and Neck Cancer Patients: Results from a Multi-center Clinical Trial. Dysphagia, 2017, 32, 327-336.	1.0	20
71	Description of a risk predictive model of 30-day postoperative mortality after elective abdominal aortic aneurysm repair. Journal of Vascular Surgery, 2017, 65, 65-74.e2.	0.6	19
72	Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. Vascular Health and Risk Management, 2016, 12, 251.	1.0	37

#	Article	IF	CITATIONS
73	Effects of intermission and resumption of longâ€term testosterone replacement therapy on body weight and metabolic parameters in hypogonadal in middleâ€aged and elderly men. Clinical Endocrinology, 2016, 84, 107-114.	1.2	43
74	Expected Sonographic Appearance of the Spleen in Children and Young Adults With Sickle Cell Disease. Journal of Ultrasound in Medicine, 2016, 35, 1735-1745.	0.8	20
75	Simple Predictive Model of Early Failure among Patients Undergoing First-Time Arteriovenous Fistula Creation. Annals of Vascular Surgery, 2016, 35, 46-52.	0.4	18
76	The Role of the Model of End-Stage Liver Disease Score in Predicting Outcomes of Carotid Endarterectomy. Vascular and Endovascular Surgery, 2016, 50, 380-384.	0.3	4
77	Alternative conduit for infrageniculate bypass in patients with critical limb ischemia. Journal of Vascular Surgery, 2016, 64, 131-139.e1.	0.6	27
78	The Author's Reply: Changing testosterone had no direct effect on HbA1c or weight in diabetic men when TRT was interrupted and then resumed. Clinical Endocrinology, 2016, 85, 500-501.	1.2	4
79	Occurrence of "never events―after major open vascular surgery procedures. Journal of Vascular Surgery, 2016, 63, 738-745.e28.	0.6	21
80	Perspectives on endovascular training in traditional 5+2 vascular surgery fellowship training programs. Vascular, 2016, 24, 134-143.	0.4	3
81	Racial Differences in Treatment Approaches and Mortality Following Arterial Trauma. Vascular and Endovascular Surgery, 2015, 49, 180-187.	0.3	8
82	Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men. Korean Journal of Urology, 2015, 56, 310.	1.2	32
83	Statistical considerations for stopping systemic lupus erythematosus clinical trials earlier. Arthritis Research and Therapy, 2015, 17, 345.	1.6	4
84	Perioperative Outcomes in Patients Requiring Iliac Conduits or Direct Access for Endovascular Abdominal Aortic Aneurysm Repair. Annals of Vascular Surgery, 2015, 29, 1548-1553.	0.4	19
85	The Association of Publication of Center for Medicaid and Medicare Services Guidelines for Carotid Artery Angioplasty and Stenting (CAS) and CREST Results on the Utilization of CAS in Carotid Revascularization. Annals of Vascular Surgery, 2015, 29, 1606-1613.	0.4	6
86	Pharmacogenomic interaction between the Haptoglobin genotype and vitamin E on atherosclerotic plaque progression and stability. Atherosclerosis, 2015, 239, 232-239.	0.4	14
87	Using Vascular Quality Initiative as a Platform for Organizing Multicenter, Prospective, Randomized Clinical Trials: OVERPAR Trial. Annals of Vascular Surgery, 2015, 29, 278-285.	0.4	20
88	Delayed myocardial recovery in peripartum cardiomyopathy. International Journal of Cardiology, 2015, 184, 310-312.	0.8	3
89	Routine use of ultrasound guidance in femoral arterial access for peripheral vascular intervention decreases groin hematoma rates. Journal of Vascular Surgery, 2015, 61, 1231-1238.	0.6	82
90	Effects of long-term testosterone replacement therapy, with a temporary intermission, on glycemic control of nine hypogonadal men with type 1 diabetes mellitus $\hat{a} \in \hat{a}$ a series of case reports. Aging Male, 2015, 18, 164-168.	0.9	33

#	Article	IF	Citations
91	Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from 5-Year Median Followup of 3 Registries. Journal of Urology, 2015, 193, 80-86.	0.2	79
92	Comparative Effects of Light or Heavy Resistance Power Training for Improving Lower Extremity Power and Physical Performance in Mobility-Limited Older Adults. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 374-380.	1.7	106
93	Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet, The, 2015, 385, 792-798.	6.3	151
94	Interventions on the Superficial Venous System for Chronic Venous Insufficiency by Surgeons in the Modern Era. Vascular and Endovascular Surgery, 2014, 48, 482-490.	0.3	13
95	Effects of Long-Term Testosterone Therapy on Patients with "Diabesity†Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes. International Journal of Endocrinology, 2014, 2014, 1-15.	0.6	90
96	Progressive Improvement of $\langle i \rangle T \langle i \rangle$ -Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years. International Journal of Endocrinology, 2014, 2014, 1-9.	0.6	26
97	Care of patients undergoing vascular surgery atÂsafety net public hospitals is associated with higher cost but similar mortality to nonsafety net hospitals. Journal of Vascular Surgery, 2014, 60, 1627-1634.	0.6	28
98	Comparison of Characteristics and Outcomes of Patients With Heart Failure Preserved Ejection Fraction Versus Reduced Left Ventricular Ejection Fraction in an Urban Cohort. American Journal of Cardiology, 2014, 113, 691-696.	0.7	45
99	Observation and surgery are associated with low risk of amputation for blunt brachial artery injury inÂpediatric patients. Journal of Vascular Surgery, 2014, 60, 443-447.	0.6	3
100	Hypogonadal obese men with and without diabetes mellitus type 2 lose weight and show improvement in cardiovascular risk factors when treated with testosterone: An observational study. Obesity Research and Clinical Practice, 2014, 8, e339-e349.	0.8	61
101	Long-Term Outcome Of Patients With AL Amyloidosis Treated With High-Dose Melphalan and Stem Cell Transplantation: 19 Year Experience At a Single Center. Blood, 2013, 122, 3328-3328.	0.6	1
102	Comparative effects of high velocity and low velocity power training on muscle performance, muscle mass and functional ability in mobilityâ€imited elders: a randomized trial. FASEB Journal, 2013, 27, 1150.2.	0.2	0
103	Risk of Second Primary Malignancies in Patients with AL Amyloidosis Treated with Lenalidomide. Blood, 2012, 120, 1873-1873.	0.6	0
104	High-Dose Melphalan and Autologous Stem Cell Transplantation In AL Amyloidosis and Monoclonal Immunoglobulin Deposition Disease Associated End-Stage Renal Disease Requiring Dialysis. Blood, 2010, 116, 3553-3553.	0.6	1
105	Outcome of Patients with AL Amyloidosis Who Do Not Achieve Hematologic Complete Response After Treatment with High Dose Melphalan and Autologous Transplantation: Results In a Series of 421 Patients. Blood, 2010, 116, 2394-2394.	0.6	1
106	Cardiac amyloidosis in African Americans: Comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis. American Heart Journal, 2009, 158, 607-614.	1,2	129
107	Comparison of lower extremity strength, power and muscle area between healthy subjects and mobilityâ€imited elders. FASEB Journal, 2008, 22, 1163.19.	0.2	0